Cord Blood Product - Worldwide

The global cord blood product market size is calculated at USD 844 million in 2024 and is predicted to reach around USD 1,362 million by 2034, expanding at a CAGR of 4.9% from 2024 to 2034.

Products derived from cord blood are used in regenerative therapy as an improved method compared to conventional bone marrow transplants. These diseases include leukemia, lymphoma, and immune deficiencies, among others, with the increasing rate of successful cord blood transplantation these products are experiencing increasing demand. In addition, the market is experiencing a growth in the trend of parents storing cord blood Newman borns for use in the future.

The cord blood product market is rapidly growing as awareness about the therapeutic potential of cord blood stem cells rises globally. Cord blood which is collected from the umbilical cord after the birth of the child, is an abundant source of hematopoietic stem cells that can be used in the management of some blood-related disorders, cancers, and genetic diseases. Opportunities in the market are increasing as technological advancements develop the efficacy and cost-effectiveness of cord blood collection, processing, and storage.

Cord blood products are in high demand due to the rising usage of stem cells in chronic disease treatment and research uses bolstering demand in the United States.